* Aclaris Therapeutics completes enrollment of phase 3
pivotal trials of A-101 for the treatment of seborrheic
keratosis (sk); provides update on clinical programs
The post BRIEF-Aclaris Therapeutics completes enrollment of late stage study for skin disorder drug appeared first on NASDAQ.